OncoMatch/Clinical Trials/NCT06611137
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Is NCT06611137 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies SBRT+Toripalimab Plus Docetaxel and Cisplatin for laryngeal cancer.
Treatment: SBRT+Toripalimab Plus Docetaxel and Cisplatin — This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T3-4N0-3M0, T2-4N0-3M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
Kidney function
normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
Liver function
normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
Cardiac function
normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify